{"id":"cessation-of-antibiotics","safety":{"commonSideEffects":[{"rate":null,"effect":"Recurrence or relapse of primary infection"},{"rate":null,"effect":"Clinical deterioration if discontinued prematurely"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Discontinuation of antibiotic therapy permits recovery of commensal bacterial flora that may have been suppressed or eliminated during treatment. This approach aims to minimize collateral damage from prolonged antibiotic exposure, including disruption of the microbiome, selection of resistant organisms, and antibiotic-associated complications such as Clostridioides difficile infection.","oneSentence":"Cessation of antibiotics allows restoration of the patient's natural microbiome and reduces antibiotic-associated adverse effects.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:05:21.096Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"De-escalation or cessation of antibiotic therapy in appropriate clinical contexts to reduce antibiotic-associated adverse effects"}]},"trialDetails":[{"nctId":"NCT07377071","phase":"EARLY_PHASE1","title":"Folate Treatment to Reduce Death Risk in the Year After Infection-Related Acute Kidney Injury","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2026-04-01","conditions":"Infection-Associated Acute Kidney Injury","enrollment":382},{"nctId":"NCT07051525","phase":"NA","title":"Early Versus Late Stopping of Antibiotics in Adults With High-risk Hematological Malignancies/Receiving Cellular Therapies and Fever","status":"RECRUITING","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2025-12-03","conditions":"Leukemia, CART Therapy, Transplantation, Stem Cell","enrollment":214},{"nctId":"NCT07115966","phase":"NA","title":"Impact of a Simple Automated Best Practice Alert (BPA) on Quantity and Quality of In-hospital Antibiotic Use in a Tertiary and Three Secondary Hospitals","status":"ACTIVE_NOT_RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2025-08-01","conditions":"Antibiotic Prescriptions, In-Patient Treatment","enrollment":58},{"nctId":"NCT07082465","phase":"","title":"Epidemiology of Antimicrobial-use and Antimicrobial-resistant Infections in Four Hospitals in Thailand","status":"NOT_YET_RECRUITING","sponsor":"University of Oxford","startDate":"2025-08-01","conditions":"Drug Resistance, Bacterial, Bacteremia","enrollment":108000},{"nctId":"NCT05192057","phase":"PHASE4","title":"Hypertonic Saline Inhalation for Mycobacterium Avium Complex Pulmonary Disease","status":"RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2022-05-20","conditions":"Nontuberculous Mycobacterial Lung Disease, Mycobacterium Avium Complex","enrollment":30},{"nctId":"NCT03388944","phase":"NA","title":"PCT Guided Stopping of Antibiotic Therapy in Children With Sepsis","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences","startDate":"2019-10-21","conditions":"Sepsis, Septic Shock, Antibiotic Use","enrollment":561},{"nctId":"NCT05350813","phase":"NA","title":"Impact of Procalcitonin-guided Algorithm on Early Discontinuation of Antibiotic Therapy","status":"RECRUITING","sponsor":"University Hospital, Toulouse","startDate":"2023-05-02","conditions":"Bacterial Infections","enrollment":296},{"nctId":"NCT01345175","phase":"PHASE3","title":"Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-04-26","conditions":"Rectal Cancer","enrollment":69},{"nctId":"NCT06278896","phase":"PHASE3","title":"Early Neutropenic Fever De-escalation of Antibiotics Study","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2024-03-01","conditions":"Hematologic Malignancy, Febrile Neutropenia, Antibiotic Stewardship","enrollment":260},{"nctId":"NCT04037787","phase":"NA","title":"ERAS (Enhanced Recovery After Surgery) Protocol Implementation in Piedmont Region for Colorectal Cancer Surgery","status":"COMPLETED","sponsor":"Ospedale Santa Croce-Carle Cuneo","startDate":"2019-09-01","conditions":"Colorectal Cancer, Quality Improvement, Perioperative Care","enrollment":2397},{"nctId":"NCT03497806","phase":"PHASE2","title":"Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection","status":"COMPLETED","sponsor":"Finch Research and Development LLC.","startDate":"2018-05-01","conditions":"Clostridium Difficile Infection, Recurrent Clostridium Difficile Infection, C. Diff","enrollment":132},{"nctId":"NCT05210673","phase":"NA","title":"Enhanced Recovery for Patients Undergoing Radical Cystectomy.","status":"COMPLETED","sponsor":"Menoufia University","startDate":"2019-09-01","conditions":"Post Procedural Discharge","enrollment":50},{"nctId":"NCT04234945","phase":"NA","title":"Effect of Prophylactic Antibiotics for Hysterosalpingography on Post Procedure Morbidity","status":"UNKNOWN","sponsor":"Ahmadu Bello University Teaching Hospital","startDate":"2020-01-13","conditions":"Infertility, Female, Pelvic Inflammatory Disease","enrollment":78},{"nctId":"NCT04063072","phase":"NA","title":"ERAS (Enhanced Recovery After Surgery) Protocol Implementation in Piedmont Region for Hysterectomy.","status":"UNKNOWN","sponsor":"Ospedale Regina Montis Regalis","startDate":"2019-09-01","conditions":"Uterine Neoplasms","enrollment":1800},{"nctId":"NCT01572831","phase":"PHASE3","title":"PCT and Clinical Algorithm for Determination of Duration of Antibiotics","status":"COMPLETED","sponsor":"Fraser Health","startDate":"2012-05","conditions":"Infection","enrollment":1}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":254,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Stop antibiotics"],"phase":"phase_3","status":"active","brandName":"Cessation of antibiotics","genericName":"Cessation of antibiotics","companyName":"Brigham and Women's Hospital","companyId":"brigham-and-women-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cessation of antibiotics allows restoration of the patient's natural microbiome and reduces antibiotic-associated adverse effects. Used for De-escalation or cessation of antibiotic therapy in appropriate clinical contexts to reduce antibiotic-associated adverse effects.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}